Organism: Homo sapiens
Gene: 38780_at
Selected probe(set): 201900_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38780_at (201900_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.859315
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.575324
Number of Samples:2 / 4

Experimental	glioma study 17 (glioblastoma; unsorted)
	Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):2.435954
Number of Samples:2 / 3

Experimental	glioma study 17 (anaplastic astrocytoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):-2.3915138
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):2.3658867
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):-2.2695208
Number of Samples:22 / 22

Experimental	systemic onset JIA study 6 (baseline; placebo)
	Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control	normal blood sample
	Whole blood samples collected from healthy volunteers.

Relative Expression (log2-ratio):-2.2017317
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Relative Expression (log2-ratio):2.1895218
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.1597204
Number of Samples:3 / 4

Experimental	expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
	Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Relative Expression (log2-ratio):2.1568956
Number of Samples:2 / 4

Experimental	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.